NIEHS Technical Report on the Subchronic Toxicity Study of 3'-Azido-3'-deoxythymidine (AZT) and Rifampicin Combinations (CAS Nos. 30516-87-1 and 13292-46-1) Administered by Gavage to B6C3F1 Mice

摘要

Male and female B6C3F1 mice were dosed orally with AZT alone (100, 200, or 400mg/kg), rifampicin alone (100, 200, or 400 mg/kg), or combinations of AZT and rifampicin for up to 94 days. Mice were evaluated for clinical findings, mean body weight, hemotology and clinical chemistry parameters, and sperm function and vaginal cytology. All core study animals and the clinical pathology study animals that died early were necropsied and subjected to histopathological evaluations. AZT along or rifampicin alone did not cause significant changes in body weights. Combination therapy with AZT and rifampicin caused marked and treatment-related decreases in body weight.